• AI Scribes Are Here, but Is Health Care Ready?
    May 6 2026

    The rise in use and function of ambient AI scribes is arguably one of the fastest technologic changes ever seen in health care. In this episode of Healthy Dialogue, host Derek Angus, MD, MPH, is joined by Vincent Liu, MD, MS, Chief Data Officer of The Permanente Medical Group in Kaiser Permanente, to discuss the rapidly changing world of ambient AI.

    Related Content:

    • Ambient AI Scribes and the Quintuple Aim
    • Changes in Clinician Time Expenditure and Visit Quantity With Adoption of Artificial Intelligence–Powered Scribes
    • AI Scribes Are Here, but Is Health Care Ready?
    Show More Show Less
    41 mins
  • Rethinking the Autism "Epidemic": What's Driving the Rise in Diagnosis
    Apr 22 2026

    What is behind the rise in autism diagnoses? Join Jeremy Veenstra-VanderWeele, MD, professor of developmental neuropsychiatry at Columbia University, and JAMA Psychiatry Editor Dost Öngür, MD, PhD, as they discuss the history of autism spectrum disorder, the role that genetics and environmental factors play, the importance of early intervention in treatment, and more with JAMA Senior Editor Derek Angus, MD, MPH.

    Related Content:

    • Autism—Understanding Diagnosis, Prevalence, and Treatment
    Show More Show Less
    36 mins
  • Introducing Healthy Dialogue
    Apr 17 2026

    Go beyond the latest discoveries with nuanced, in-depth conversations in Healthy Dialogue, a podcast from the JAMA Network. Host and JAMA Senior Editor, Derek C. Angus, MD, MPH, sits down with the world's leading experts to explore the most pressing issues in health and health care.

    Show More Show Less
    2 mins
  • From the JAMA Network: JAMA Research of the Year With Editor in Chief Kirsten Bibbins-Domingo
    Dec 26 2025

    In this episode, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and Medical News Director Jennifer Abbasi discuss the journal's inaugural Research of the Year roundup.

    Related Content:

    • Research of the Year 2025
    Show More Show Less
    16 mins
  • The Sequential Organ Failure Assessment (SOFA)-2 Score
    Oct 29 2025

    SOFA-2, validated in more than 3 million intensive care unit (ICU) patients, incorporates contemporary organ support treatments, showing strong predictive validity for ICU mortality in diverse international settings. Coauthor Mervyn Singer, MD, joins JAMA Associate Editor Christopher W. Seymour, MD, MSc, to discuss.

    Related Content:

    • Rationale and Methodological Approach Underlying the Development of the Sequential Organ Failure Assessment (SOFA)–2 Score
    • Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score
    • A Revision to Organ Failure Assessment in Critically Ill Patients
    Show More Show Less
    16 mins
  • From the JAMA Network: Acetaminophen Use in Pregnancy and Risk of Autism
    Sep 30 2025

    Epidemiologist Brian Lee, PhD, discusses his study on acetaminophen use during pregnancy and children's risk of autism and other neurodevelopmental disorders in this interview with JAMA Deputy Editor Linda Brubaker, MD.

    Related Content:

    • Acetaminophen Use in Pregnancy—Study Author Explains the Data
    Show More Show Less
    17 mins
  • From the JAMA Network: AI-Based Analysis for Parkinsonism
    Aug 30 2025

    Delaying diagnosis of parkinsonism can mean delaying care. In a study recently published in JAMA Neurology, David Vaillancourt, PhD, and colleagues tested the ability of an AI model to differentiate between Parkinson disease and other neurodegenerative disorders when paired with MRI. He joins JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH to discuss.

    Related Content:

    • A Large Proportion of Parkinson Disease Diagnoses Are Wrong—Here's How AI Could Help
    • Automated Imaging Differentiation for Parkinsonism
    Show More Show Less
    12 mins
  • Treatment of Complicated Staphylococcus aureus Bacteremia
    Aug 13 2025

    Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ.

    Related Content:

    • Dalbavancin for Treatment of Staphylococcus aureus Bacteremia
    • Management of Staphylococcus aureus Bacteremia
    Show More Show Less
    12 mins